- Visibility 301 Views
- Downloads 613 Downloads
- Permissions
- DOI 10.18231/j.ijogr.v.12.i.3.19
-
CrossMark
Real-world evaluation of safety and effectiveness of dydrogesterone 20mg extended release in the management of recurrent early pregnancy loss
- Author Details:
-
Ameya C Purandare
-
Rujul Jhaveri
-
Vaidehi Marathe
-
Ratnadeep Goswami
-
Rooplekha Chauhan
-
Ashok Jaiswal
-
Bhavya Shetty *
Ashok Jaiswal
Background: Recurrent early pregnancy loss (REPL) is a distressing condition affecting 1% to 5% of couples globally. Progesterone plays a crucial role in maintaining pregnancy, and dydrogesterone, a synthetic progestogen, has emerged as a promising therapeutic option due to its selective action and favorable safety profile. With introduction of extended release (ER) formulations of dydrogesterone 20 mg, real-world data on its effectiveness and safety in REPL is not documented.
Materials and Methods: This was a retrospective, multicentric, observational study conducted from the data obtained of patients with history of REPL treated with dydrogesterone 20 mg ER at the discretion of treating physician. Patient data were collected using standardized Case Report Forms (CRFs), and outcomes included miscarriage incidence, pregnancy continuation, and adverse events. Data were analyzed to evaluate the safety, and effectiveness of dydrogesterone 20 mg ER.
Results: The study included data of 828 patients with history of REPL and treated with dydrogesterone 20 mg ER. The analysis reported an incidence of miscarriage in 64 patients (7.7%), with the majority of patients (92.3%) continuing pregnancy beyond 20 weeks of gestation. Among patients who experienced miscarriage (n=64), the mean gestational age at the time of visit was 6.88 ± 2.12 weeks and at the time of miscarriage was found to be 10.62 ± 3.17 weeks. A total of 77 (9.3%) patients developed adverse events during the treatment period and among them 80% of the adverse events were mild in nature.
Conclusion: Dydrogesterone 20 mg ER is safe and effective in managing REPL, demonstrating a low miscarriage rate and prolonged pregnancy continuation beyond 20 weeks. These findings provide real-world evidence supporting its role as a practical therapeutic option for REPL.
References
- Ford HB, Schust DJ. Recurrent pregnancy loss: etiology, diagnosis, and therapy. Rev Obstet Gynecol. 2009;2(2):76–83.
- Li X, Peng A, Li L, Chen L. The association between repeated abortions during childbearing age and the psychological well-being of postmenopausal women in Southwest China: an observational study. BMC Pregnancy Childbirth. 2024;24(1):805.
- Eleje GU, Ugwu EO, Igbodike EP, Malachy DE, Nwankwo EU, Ugboaja JO, et al. Prevalence and associated factors of recurrent pregnancy loss in Nigeria according to different national and international criteria (ASRM/ESHRE vs. WHO/RCOG). Front Reprod Health. 2023;5:1049711.
- El Hachem H, Crepaux V, May-Panloup P, Descamps P, Legendre G, Bouet PE, et al. Recurrent pregnancy loss: current perspectives. Int J Womens Health. 2017;9:331–45.
- Tesarik J, Conde-López C, Galán-Lázaro M, Mendoza-Tesarik R. Luteal phase in assisted reproductive technology. Front Reprod Health. 2020;2:595183.
- Palomba S, Santagni S, La Sala GB. Progesterone administration for luteal phase deficiency in human reproduction: an old or new issue? J Ovarian Res. 2015;8:77.
- de Assis V, Giugni CS, Ros ST. Evaluation of Recurrent Pregnancy Loss. Obstet Gynecol. 2024;143(5):645–59.
- Dante G, Vaccaro V, Facchinetti F. Use of progestagens during early pregnancy. Facts Views Vis Obgyn. 2013;5(1):66–71.
- Griesinger G, Blockeel C, Tournaye H. Oral dydrogesterone for luteal phase support in fresh in vitro fertilization cycles: a new standard? Fertil Steril. 2018;109(5):756–62.
- Muneeba S Jr, Acharya N, Mohammad S. the role of dydrogesterone in the management of luteal phase defect: A comprehensive review. Cureus. 2023;15(11):e48194.
- Guo H, Lu Q. Efficacy of dydrogesterone on treating recurrent miscarriage and its influence on immune factors: a systematic review and meta-analysis. Ann Palliat Med. 2021;10(10):10971–85.
- Mackens S, Brucker MD, Illingworth K, Tournaye H, Blockeel C. Oral dydrogesterone (OD) versus micronized vaginal progesterone (MVP) for luteal phase support (LPS) in IVF/ICSI: a double blind, cross-over, pharmacokinetic study. Hum Reprod. 2021;36:418–9.
- Mirza FG, Patki A, Pexman-Fieth C. Dydrogesterone use in early pregnancy. Gynecological Endocrinology 2016;32(2):97–106.
- El-Zibdeh MY. Dydrogesterone in the reduction of recurrent spontaneous abortion. J Steroid Biochem Mol Biol. 2005;97(5):431–
- Bashiri A, Galperin G, Zeadna A, Baumfeld Y, Wainstock T. Increased live birth rate with dydrogesterone among patients with recurrent pregnancy loss regardless of other treatments. J Clin Med. 2023;12(5):1967.
- Guo H, Lu Q. Efficacy of dydrogesterone on treating recurrent miscarriage and its influence on immune factors: a systematic review and meta-analysis. Ann Palliat Med. 2021;10(10):10971–85.
- Ott J, Egarter C, Aguilera A. Dydrogesterone after 60 years: a glance at the safety profile. Gynecol Endocrinol. 2022;38(4):279–87.
- Raghupathy R, Al Mutawa E, Makhseed M, Azizieh F, Szekeres- Bartho J. Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent miscarriage. BJOG. 2005;112(8):1096–101.